Evogene Stock Price, News & Analysis

Biomica Ltd., a subsidiary of Evogene (Nasdaq: EVGN), announced the dosing of the first patient in its Phase I clinical trial of BMC128, a microbiome-based drug candidate for immuno-oncology. This trial assesses safety and tolerability in patients with non-small cell lung cancer, melanoma, or renal cell carcinoma, using Bristol Myers Squibb's Opdivo® as an immune checkpoint inhibitor. Preliminary results are anticipated in early 2023, with the study aiming for completion by H2-2023. BMC128 is designed to enhance anti-tumor immunity via a unique microbial consortium identified through advanced microbiome analysis.

Biomica Ltd., a biopharmaceutical company specializing in microbiome-based therapeutics and a subsidiary of Evogene (NASDAQ: EVGN), will present at Microbiome Connect Europe in Amsterdam on July 6-7, 2022. Dr. Shiri Meshner, VP R&D at Biomica, will participate in a panel discussing gut microbiota's role in cancer therapy on July 6 at 11:30am CET and will present updates on BMC128, a live bacterial consortium for enhancing immune checkpoint therapy, on July 7 at 3:45pm CET. One-on-one meetings with Dr. Meshner are available for interested parties.

Biomica Ltd. announced its participation in the 7th Microbiome Movement Drug Development Summit, taking place from June 21-24, 2022, in Boston, MA. Dr. Elran Haber, CEO of Biomica, will join the opening panel on June 22, 2022. This summit is recognized as a key platform for microbiome drug developers, focusing on next-generation microbiome-based therapeutics and fostering industry collaborations. Biomica, a subsidiary of Evogene Ltd. (NASDAQ: EVGN), specializes in developing microbiome-based therapies targeting antibiotic-resistant bacteria and GI disorders.

Evogene Ltd. (NASDAQ: EVGN) reported its Q1 2022 financial results, showing revenues of $237K, a decline from $333K in Q1 2021. The company maintains a strong cash position of approximately $45 million. R&D expenses increased to $5.6 million from $4.3 million year-over-year, primarily due to ongoing clinical preparations. The net loss for the quarter was $9.1 million, up from $7.1 million in Q1 2021. Significant milestones include Biomica's positive pre-clinical results for BMC333 and the initiation of its first-in-human study. Lavie Bio's product 'result™' has shown potential yield improvements for growers amidst rising wheat prices.

Biomica Ltd., a biopharmaceutical subsidiary of Evogene (NASDAQ: EVGN), will present its research at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The presentation, titled "A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors," has been selected for a poster session and the GRASP Advocate Choice Award. Dr. Corinne Maurice-Dror will present on June 5, 2022. Biomica is focused on microbiome-based therapeutics for antibiotic resistance and immuno-oncology.

Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), will present at Digestive Disease Week (DDW) 2022 in San Diego, California, from May 21-24. Professor Yehuda Ringel, Biomica's CSO, is scheduled to speak on May 22 from 4:00 PM to 5:30 PM PDT about the anti-inflammatory effects of a live bacterial consortium for treating Inflammatory Bowel Disorders (IBD). This presentation will share findings from pre-clinical research on microbiome-based drug development. Biomica focuses on microbiome therapeutics for gastrointestinal disorders and bacterial resistance.

Lavie Bio Ltd., a subsidiary of Evogene (NASDAQ: EVGN), reports strong demand for its bio-inoculant result™ during the 2022 growing season, successfully selling its entire production to U.S. customers. This demand is driven by rising global wheat prices due to shortages exacerbated by the Russia-Ukraine conflict. Field trials indicate result™ can enhance yields by 3-4 bushels per acre, translating to an additional $30-40 in revenue per acre for farmers. The company plans to increase production for the 2023 season and expand sales to Canada and Europe.